No­var­tis promis­es a speedy CAR-T pitch, boasts about its slate of block­busters-to-be

No­var­tis sent out a loud and clear mes­sage this morn­ing: De­spite fold­ing its stand­alone cell ther­a­py unit, the phar­ma gi­ant says it re­mains on track to de­liv­er an ap­pli­ca­tion for its CAR-T CTL-019 for pe­di­atric acute lym­phoblas­tic leukemia “in ear­ly 2017.” And an ap­pli­ca­tion for dif­fuse large B cell lym­phoma is due in the sec­ond half of next year, which could put it well be­hind ri­val Kite Phar­ma. At the same time, the phar­ma gi­ant — now un­der as­sault from gener­ic com­pe­ti­tion — boast­ed about a dozen late-stage pro­grams with block­buster po­ten­tial to earn more than a bil­lion dol­lars a year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER